ACE inhibitors and angiotensin II receptor antagonists

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Angiotensin II (ANG), a key hormone in the renin-angiotensin-aldosterone system (RAAS), significantly contributes to cardiovascular disease development.
• ANG exacerbates hypertension, metabolic syndrome, and endothelial dysfunction, acting as a major risk factor for atherosclerosis.
• The hormone influences atherosclerotic lesion formation through lipid metabolism, inflammation, and cellular proliferation, primarily via the AT1 receptor.

Purpose of the Study:

• To review the multifaceted biological actions of Angiotensin II (ANG) in promoting atherosclerosis and cardiovascular pathology.
• To evaluate the therapeutic efficacy of ANG-suppressing drugs, including ACE inhibitors (ACEI) and AT1 receptor blockers (ARB), in preclinical and clinical settings.
• To elucidate the mechanisms underlying the clinical benefits of RAAS inhibitors in cardiovascular disease management.

Main Methods:

• Review of preclinical studies demonstrating ANG's role in atherosclerosis and restenosis.
• Analysis of in vitro data showing the effects of ACEI and ARB on ANG-mediated pathways.
• Examination of clinical trial data on the efficacy of ACEI and ARB in hypertension, heart failure, and coronary heart disease.

Main Results:

• Both ACEI and ARB effectively attenuate various pathomechanisms of ANG in vitro and reduce atherosclerotic lesions in animal models.
• Clinically, ACEI are well-tolerated antihypertensive drugs that improve outcomes in heart failure and post-myocardial infarction patients.
• Evidence for RAAS inhibitors' efficacy against arterial restenosis is limited, and their role in primary prevention of coronary heart disease is debated.

Conclusions:

• The general clinical efficacy of ACEI and ARB may stem from beneficial effects on hemodynamics, vascular function, and neuro-humoral regulation, rather than direct anti-atherosclerotic action.
• Further research is needed to optimize drug selection, patient populations, and treatment protocols for maximizing therapeutic advances.
• ANG plays a critical role in cardiovascular disease, and its inhibition offers significant clinical benefits, though the precise mechanisms require further investigation.